Topsalysin
- Generic Name
- Topsalysin
- Drug Type
- Small Molecule
- CAS Number
- 917121-25-6
- Unique Ingredient Identifier
- LSA9D0A43Q
- Background
Topsalysin is being developed for the treatment of localized prostate cancer and also benign prostatic hyperplasia. Topsalysin is delivered locally to the prostate under ultrasound guidance.
- Indication
Investigated for use/treatment in benign prostatic hyperplasia, cancer/tumors (unspecified), prostate cancer, prostate disorders, and solid tumors.
Intraprostatic PRX302 Injection to Treat Localised Prostate Cancer
- First Posted Date
- 2017-03-16
- Last Posted Date
- 2019-04-10
- Lead Sponsor
- Sophiris Bio Corp
- Target Recruit Count
- 38
- Registration Number
- NCT03081481
- Locations
- 🇺🇸
Chesapeake Urology Associates, Baltimore, Maryland, United States
🇬🇧Imperial College, London, United Kingdom
🇺🇸New York Urology Associates, New York, New York, United States
Evaluate, Safety and Tolerability of Intraprostatic PRX302 Administration, Low to Intermediate Risk Prostate Cancer
- First Posted Date
- 2015-07-16
- Last Posted Date
- 2016-07-27
- Lead Sponsor
- Sophiris Bio Corp
- Target Recruit Count
- 18
- Registration Number
- NCT02499848
- Locations
- 🇬🇧
UCLH, London, United Kingdom
Randomized, Double-Blind, Vehicle-Controlled, Multicenter Safety and Efficacy Study of Intraprostatic PRX302 for LUTS BPH
- First Posted Date
- 2013-10-21
- Last Posted Date
- 2017-04-27
- Lead Sponsor
- Sophiris Bio Corp
- Target Recruit Count
- 479
- Registration Number
- NCT01966614
Study of PRX302 for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia (BPH)
- First Posted Date
- 2011-10-19
- Last Posted Date
- 2013-08-21
- Lead Sponsor
- Sophiris Bio Corp
- Target Recruit Count
- 40
- Registration Number
- NCT01454349
- Locations
- 🇺🇸
Atlantic Urology Medical Group, Long Beach, California, United States
🇺🇸The Iowa Clinic, West Des Moines, Iowa, United States
🇺🇸Accumed Research Associates, Garden City, New York, United States
Transperineal Intraprostatic Injection of PRX302 Under Ultrasound Guidance for Management of Prostatic Hyperplasia
- First Posted Date
- 2009-04-29
- Last Posted Date
- 2018-11-21
- Lead Sponsor
- Sophiris Bio Corp
- Target Recruit Count
- 92
- Registration Number
- NCT00889707
- Locations
- 🇨🇦
The Fe/Male Health Centers, Oakville, Ontario, Canada
🇨🇦Brantford Urology Research, Brantford, Ontario, Canada
🇨🇦Urology Associates / Urology Medical Research, Kitchener, Ontario, Canada
An Open-Label, Multi-Center, Phase IIa Trial of PRX302 Treatment of Patients With Locally Recurrent Prostate Cancer After Primary Radiation Therapy
- Conditions
- Locally Recurrent Prostate Cancer
- First Posted Date
- 2008-05-29
- Last Posted Date
- 2009-10-29
- Lead Sponsor
- Sophiris Bio Corp
- Target Recruit Count
- 30
- Registration Number
- NCT00686088
- Locations
- 🇺🇸
Urology San Antonio, San Antonio, Texas, United States
🇺🇸Scott & White Memorial Hospital, Temple, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.